| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CCNE; Pccne1 |
| Entrez GeneID | 898 |
| clone | 1C8D4 |
| WB Predicted band size | 47kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CCNE1 (AA: 1-100) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CCNE1抗体的3篇参考文献示例(内容为模拟概括，仅供参考)：
1. **文献名称**：*CCNE1 amplification is associated with poor prognosis in ovarian cancer*
**作者**：Etemadmoghadam, D., et al.
**摘要**：该研究通过免疫组化(使用兔抗CCNE1多克隆抗体)和基因扩增分析，发现CCNE1在高级别浆液性卵巢癌中的过表达与患者总生存期缩短显著相关，提示其作为预后标志物的潜力。
2. **文献名称**：*Cyclin E1 as a predictive biomarker for resistance to CDK4/6 inhibitors in breast cancer*
**作者**：Meng, T., et al.
**摘要**：研究利用Western blot(小鼠抗CCNE1单克隆抗体，克隆号HE12)和基因测序技术，揭示CCNE1高表达与乳腺癌患者对CDK4/6抑制剂治疗耐药相关，为个体化治疗提供依据。
3. **文献名称**：*Validation of CCNE1 antibody specificity in cancer cell lines*
**作者**：Lee, K., et al.
**摘要**：该文献系统评估了多种市售CCNE1抗体(包括兔单抗和人源化抗体)的特异性，通过siRNA敲低实验和质谱验证，确认了部分抗体在检测肿瘤样本中CCNE1蛋白水平的可靠性。
(注：上述文献信息为示例性模拟，实际引用时请核对真实文献。)
The CCNE1 antibody targets cyclin E1. a key regulatory protein involved in cell cycle progression, specifically the G1-to-S phase transition. Cyclin E1 forms a complex with cyclin-dependent kinase 2 (CDK2), promoting phosphorylation of retinoblastoma (Rb) protein and facilitating the release of E2F transcription factors, which drive DNA replication. Overexpression of CCNE1 is frequently observed in various cancers, including ovarian, breast, and gastric cancers, and is associated with genomic instability, tumor aggressiveness, and poor prognosis. This dysregulation often stems from gene amplification, transcriptional upregulation, or protein stabilization.
CCNE1 antibodies are essential tools in biomedical research for detecting and quantifying cyclin E1 expression in cells and tissues. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study its role in cell cycle dynamics, cancer progression, and therapeutic resistance. In clinical contexts, CCNE1 expression levels are evaluated as potential biomarkers for patient stratification or predictors of chemotherapy response. Additionally, research into CCNE1 inhibitors as targeted therapies has spurred the development of companion diagnostic assays using these antibodies. Validation of CCNE1 antibodies includes specificity checks via knockout cell lines or siRNA-mediated silencing, ensuring accurate detection in both research and diagnostic applications.
×
